| |
Steve:
I have not been paid one dime to write a report and follow the company for almost one year now. ANTX has also never attended any of our conferences. In fact, I invited them in June and they declined. Yet I still follow them. Why???? Because I enjoy the story, have a lot of experience with vaccines development, believe ANTX shares to be ridiculously undervalued, and have posted on each of these themes many, many times.
This type of journalism can be creative; but you know that better than anyone for as much as you have published about ILT during its 1997 run from 14 to 3. It must have been terrible to have a financial interest in a Britesmile location or ILT stock this year, huh Steve? I guess such financial interests might make someone post lots of diatribes on the internet about the virtues of the parent company and the potential pitfalls about its competition, wouldn't it Steve? You, sir, are a walking equal and opposite reaction to the realities behind that which you present. Your approach could not be more dissimilar to mine, especially as it pertains to ANTX.
If I, and all the others on the board are correct, ANTX could support today a valuation of over $3.00, and up to $10.00 based on its collaborations and pipeline if it were Nasdaq listed and all outstanding warrants were exercised. The company also mitigates its burn rate exceptionally, a genuine plus in biotech. Trouble is, they can't get sell side brokerage research on them because they don't need to raise money. Mutual funds wont look at them because their capitalization is too small.
How does the word get out on such a gem you ask? Firms like Westergaard Online bring the microcap company to the small online investor like you, Steve. I write a FREE report and 200 people download it from the Internet (no kidding). In immediate (or even ultimate) return, I get NOTHING, except the risk of my reputation in that I may be wrong about the stock, near term, mid term, long term or all of the above. However, I assume this risk because I have confidence in my analytical skills. I ask if Noonan Russo, ANTX' high-priced IR firm (as of Jan 2, 1997) has given the company anywhere near the exposure that I and others (like Mike Vitas) have given ANTX in last six weeks (or ever)? I'll let the rest of the board answer that one.
From my vantage Steve, firms like N&R (as they have handled ANTX), should be the target of your rage. But you have an axe to grind with my boss and not these firms, so your motivation manifests again.
FJA
PS - Thanks for the correction on the pink sheets, I didn't even consider it for ANTX because they have been filing for years. My mistake and education. |
|
